Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
Guangzhou Baiyunshan Pharmaceutical Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Guangzhou Baiyunshan Pharmaceutical Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 2.9% bzw. 6.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich sinken um 4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.6% betragen.
Wichtige Informationen
2.9%
Wachstumsrate der Gewinne
-4.0%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 19.1% |
| Wachstumsrate der Einnahmen | 6.1% |
| Zukünftige Eigenkapitalrendite | 10.6% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 19 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Keine Aktualisierungen
Recent updates
The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 90,933 | 4,415 | N/A | 3,638 | 3 |
| 12/31/2025 | 85,609 | 4,436 | N/A | 4,546 | 6 |
| 12/31/2024 | 81,088 | 4,350 | N/A | 5,229 | 2 |
| 3/31/2024 | 76,833 | 4,105 | 2,092 | 3,804 | N/A |
| 12/31/2023 | 75,515 | 4,056 | 2,475 | 4,104 | N/A |
| 9/30/2023 | 74,167 | 4,283 | 2,958 | 4,601 | N/A |
| 6/30/2023 | 73,538 | 4,188 | 2,954 | 4,546 | N/A |
| 3/31/2023 | 71,878 | 4,069 | 1,898 | 3,242 | N/A |
| 12/31/2022 | 70,788 | 3,967 | 5,615 | 6,999 | N/A |
| 9/30/2022 | 70,280 | 3,883 | 1,805 | 3,187 | N/A |
| 6/30/2022 | 70,106 | 3,807 | 3,878 | 5,201 | N/A |
| 3/31/2022 | 69,507 | 3,898 | 3,606 | 4,910 | N/A |
| 12/31/2021 | 69,014 | 3,720 | 4,419 | 5,673 | N/A |
| 9/30/2021 | 68,329 | 3,568 | 4,862 | 5,982 | N/A |
| 6/30/2021 | 67,333 | 3,653 | 4,133 | 5,174 | N/A |
| 3/31/2021 | 64,735 | 3,359 | 4,726 | 5,674 | N/A |
| 12/31/2020 | 61,674 | 2,915 | -291 | 585 | N/A |
| 9/30/2020 | 61,774 | 2,688 | 3,526 | 4,389 | N/A |
| 6/30/2020 | 62,081 | 2,406 | 2,641 | 3,543 | N/A |
| 3/31/2020 | 63,881 | 2,966 | 2,041 | 4,414 | N/A |
| 12/31/2019 | 64,952 | 3,189 | 2,623 | 5,022 | N/A |
| 9/30/2019 | 62,420 | 3,161 | 563 | 2,884 | N/A |
| 6/30/2019 | 60,735 | 3,370 | 911 | 3,088 | N/A |
| 3/31/2019 | 53,380 | 3,943 | 1,003 | 1,616 | N/A |
| 12/31/2018 | 42,234 | 3,441 | 4,738 | 5,217 | N/A |
| 9/30/2018 | 34,863 | 4,015 | 3,077 | 3,378 | N/A |
| 6/30/2018 | 24,679 | 3,523 | 1,918 | 2,171 | N/A |
| 3/31/2018 | 22,575 | 2,482 | 2,065 | 2,280 | N/A |
| 1/1/2018 | 20,954 | 2,062 | N/A | 1,834 | N/A |
| 9/30/2017 | 20,459 | 1,937 | N/A | 1,888 | N/A |
| 6/30/2017 | 20,294 | 1,834 | N/A | 1,649 | N/A |
| 3/31/2017 | 20,273 | 1,583 | N/A | 2,157 | N/A |
| 12/31/2016 | 20,036 | 1,508 | N/A | 2,545 | N/A |
| 9/30/2016 | 19,598 | 1,397 | N/A | 2,806 | N/A |
| 6/30/2016 | 19,502 | 1,357 | N/A | 2,427 | N/A |
| 3/31/2016 | 19,442 | 1,345 | N/A | 2,442 | N/A |
| 12/31/2015 | 19,125 | 1,300 | N/A | 1,942 | N/A |
| 9/30/2015 | 19,244 | 1,300 | N/A | 1,499 | N/A |
| 6/30/2015 | 19,270 | 1,295 | N/A | 1,859 | N/A |
| 3/31/2015 | 18,876 | 1,241 | N/A | 1,827 | N/A |
| 12/31/2014 | 18,818 | 1,194 | N/A | 1,749 | N/A |
| 9/30/2014 | 19,049 | 1,106 | N/A | 1,902 | N/A |
| 6/30/2014 | 18,563 | 1,067 | N/A | 1,136 | N/A |
| 3/31/2014 | 18,130 | 1,036 | N/A | 895 | N/A |
| 12/31/2013 | 17,608 | 980 | N/A | 1,336 | N/A |
| 9/30/2013 | 16,744 | 891 | N/A | 1,253 | N/A |
| 6/30/2013 | 15,485 | 889 | N/A | 1,585 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 874Das prognostizierte Gewinnwachstum (2.9% pro Jahr) liegt über der Sparquote (2.2%).
Ertrag vs. Markt: 874Die Erträge des Unternehmens (2.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (12% pro Jahr).
Hohe Wachstumserträge: 874Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: 874Die Einnahmen des Unternehmens (6.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (7.9% pro Jahr).
Hohe Wachstumseinnahmen: 874Die Einnahmen des Unternehmens (6.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 874Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.6 %).